{"id":1906,"date":"2019-09-26T18:29:17","date_gmt":"2019-09-26T16:29:17","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=1906"},"modified":"2024-06-19T14:21:52","modified_gmt":"2024-06-19T12:21:52","slug":"malalties-de-cap-i-coll","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-moleculars-i-terapia-experimental-en-oncologia-oncobell\/malalties-de-cap-i-coll\/","title":{"rendered":"Malalties de cap i coll"},"content":{"rendered":"\n<h1>\n\t\tMalalties de cap i coll\n\t<\/h1>\n<h3>\n\t\tResum\n\t<\/h3>\n\t<p>El grup de recerca de cap i coll, en la seva l\u00ednia de recerca oncol\u00f2gica, estudia noves dianes terap\u00e8utiques i biomarcadors predictius de resposta a QMT, RT i immunoter\u00e0pia, el paper del virus del papil\u00b7loma hum\u00e0 (HPV) i el maneig diferencial dels tumors HPV+, el tractament trans-oral del C\u00e0ncer de Laringe amb l\u00e0ser CO2 i Cirurgia Rob\u00f2tica, cirurgia reconstructiva i rehabilitaci\u00f3 fonat\u00f2ria dels pacients laringectomitzats.<\/p>\n<h2>406<\/h2>\n<h2>Publicacions<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/04\/511-malaltiescapcoll-mmanos-def.jpg\" alt=\"511-malaltiescapcoll-mmanos-def\" itemprop=\"image\" height=\"300\" width=\"600\" title=\"511-malaltiescapcoll-mmanos-def\" onerror=\"this.style.display='none'\"  \/>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\">L\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-0\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-0\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Papilomatosi respirat\u00f2ria recurrent. aspectes etiol\u00f2gics, cl\u00ednics i de tractament, efectes de les vacunes en l&#8217;evoluci\u00f3 i el control d&#8217;aquesta malaltia.<\/li>\n<li>La nova era de la cirurgia d&#8217;orelles: cirurgia endosc\u00f2pica d&#8217;orelles, t\u00e8cniques segures i resultats.<\/li>\n<li>Impactes de la composici\u00f3 corporal al c\u00e0ncer de cap i coll<\/li>\n<li>Noves t\u00e8cniques per al maneig quir\u00fargic de la telangiect\u00e0sia hemorr\u00e0gica heredit\u00e0ria (malaltia de Rendu-Osler-Weber)<\/li>\n<li>Els efectes dels tractaments biol\u00f2gics a la rinosinusitis cr\u00f2nica amb poliposis.<\/li>\n<li>Radi\u00f2mica i tumors de cap i coll<\/li>\n<li>La implementaci\u00f3 de la intel\u00b7lig\u00e8ncia artificial en el diagn\u00f2stic i maneig dels tumors de cap i coll<\/li>\n<li>Avaluaci\u00f3 per AC de l&#8217;anatomia dels sins paranasals per millorar els resultats i la seguretat de la cirurgia endosc\u00f2pica funcional dels sins paranasals<\/li>\n<li>Implementaci\u00f3 i resultats de la cirurgia rob\u00f2tica en c\u00e0ncer de cap i coll<br \/>\nVPH i c\u00e0ncer de cap i coll<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\">Publicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-1\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-1\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>Spreaflco,A;Heirali,AA;Araujo,DV;Tan,TJ;Oliva,M;Schneeberger,PHH;Chen,B et al, <strong>First-in-class Microbial Ecosystem Therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial)<\/strong>, Ann. Oncol., 2023;34(6):520-530, doi:10.1016\/j.annonc.2023.02.011<\/li>\n<li>Mosteiro,M;Azuara,D;Villatoro,S;Alay,A;Gausachs,M;Varela,M;Baixeras,N et al, <strong>Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre<\/strong>, ESMO Open, 2023;8(6):doi:10.1016\/j.esmoop.2023.102197<\/li>\n<li>Hijazo Pechero,S;Alay,A;Cordero,D;Marin,R;Vilari\u00f1o,N;Palmero,R;Brenes,J et al, <strong>Transcriptional analysis of landmark molecular pathways in lung adenocarcinoma results in a clinically relevant classification with potential therapeutic implications<\/strong>, Mol. Oncol., 2023;18(2):453-470, doi:10.1002\/1878-0261.13550<\/li>\n<li>Naval Baudin,P;Pons Escoda,A;Camins,\u00c0;Arroyo,P;Viveros,M;Castell,J;Cos,M et al, <strong>Deeply 3D-T1-TFE hypointense voxels are characteristic of phase-rim lesions in multiple sclerosis<\/strong>., Eur. Radiol., 2023;34(2):1337-1345, doi:10.1007\/s00330-023-09784-w<\/li>\n<li>Maj\u00f3s,C;Pons Escoda,A;Naval,P;Guell,A;Lucas,A;Vidal,N;Cos,M et al, <strong>Proton MR spectroscopy shows improved performance to segregate high-grade astrocytoma subgroups when defined with the new 2021 World Health Organization classification of central nervous system tumors<\/strong>, Eur. Radiol., 2023;doi:10.1007\/s00330-023-10138-9<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\">Projectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-2\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-2\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<ul>\n<li>19ACL261. <strong>ESTUDIO CL\u00cdNICO DE FASE 3, ALEATORIZADO, DOBLE CIEGO Y CONTROLADO CON PLACEBO DE PEMBROLIZUMAB (MK-3475) CON O SIN LENVATINIB (E7080\/MK-7902) PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE PEMBROLIZUMAB Y LENVATINIB COMO INTERVENCI\u00d3N DE PRIMERA L\u00cdNEA EN UNA P<\/strong>. MERCK SHARP &amp; DOHME ESPA\u00d1A S.A.. Budget: 313.548\u20ac. 2019- . PI: OLIVA BERNAL, MARC.<\/li>\n<li>20ACL093. <strong>A RANDOMIZED, DOUBLE-BLIND, ADAPTIVE, PHASE II\/III STUDY OF GSK3359609 OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE RECURRENT\/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA<\/strong>. GlaxoSmithKline Research &amp; Development Limited;GlaxoSmithKline, S.A. Budget: 236.335,84\u20ac. 2020- . PI: Plana Serrahima, Mar\u00eda.<\/li>\n<li>2023-491-1. <strong>PHASE 1-2 STUDY INVESTIGATING SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF ANTI-TIM-3 MONOCLONAL ANTIBODY BGB-A425 IN COMBINATION WITH ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS<\/strong>. BEIGENE SWITZERLAND GMBH. Budget: 233.370\u20ac. 2023- . PI: OLIVA BERNAL, MARC.<\/li>\n<li>20ACL112. <strong>Estudio cl\u00ednico de fase 2, aleatorizado, abierto y de tres grupos para evaluar la seguridad y la eficacia de lenvatinib (E7080\/MK-7902) en combinaci\u00f3n con pembrolizumab (MK-3475) frente a la quimioterapia de referencia y lenvatinib en monoterapia en parti<\/strong>. MERCK SHARP &amp; DOHME ESPA\u00d1A S.A.. Budget: 215.055\u20ac. 2020- . PI: Taberna Sanz, Miren.<\/li>\n<li>2023-351-1. <strong>ENSAYO DE FASE I, ABIERTO, DE ESCALADO DE DOSIS DE BI 1831169 EN MONOTERAPIA Y EN COMBINACI\u00d3N CON EZABENLIMAB EN PACIENTES CON TUMORES S\u00d3LIDOS AVANZADOS O METAST\u00c1SICOS<\/strong>. Boehringer Ingelheim Espa\u00f1a, S.A.. Budget: 201.126\u20ac. 2023- . PI: OLIVA BERNAL, MARC.<\/li>\n<\/ul>\n\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--label-3\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-3\">M\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-accordion--icon-3\" tabindex=\"0\" aria-controls=\"fl-accordion--panel-3\"><i>Expand<\/i><\/a>\n\t\t\t\t\t<p>Actualment els projectes m\u00e9s rellevants estan dirigits a l&#8217;estudi del c\u00e0ncer d&#8217;orofaringe, sobretot en pacients HPV positius, \u00a0a la recerca de biomarcadors de pron\u00f2stic i agressivitat de la malaltia per adequar-hi el tractament adient, aix\u00ed com a la recerca d&#8217;una signatura gen\u00e8tica \u00a0per a cercar un tractament m\u00e9s personalitzat en pacients amb c\u00e0ncer d&#8217;orofaringe.<\/p>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/04\/Manel-Ma\u00f1os-150x150.jpg\" alt=\"Manel Ma\u00f1os\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Manel Ma\u00f1os\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tMa\u00f1os Pujol, Manel\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:mmanos@idibell.cat\" title=\"mmanos@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tmmanos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/04\/Manel-Ma\u00f1os-150x150.jpg\" alt=\"Manel Ma\u00f1os\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Manel Ma\u00f1os\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tMa\u00f1os Pujol, Manel\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:mmanos@idibell.cat\" title=\"mmanos@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tmmanos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2021\/06\/Marc-Oliva-Bernal-150x150.jpg\" alt=\"Marc-Oliva-Bernal\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Marc-Oliva-Bernal\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tOliva Bernal, Marc \n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:moliva@idibell.cat\" title=\"moliva@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tmoliva@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t<img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/idibell.cat\/wp-content\/uploads\/2021\/06\/Lorena-Arribas-Hortiguela.jpg\" alt=\"Lorena-Arribas-Hortig\u00fcela\" itemprop=\"image\" height=\"150\" width=\"150\" title=\"Lorena-Arribas-Hortig\u00fcela\" onerror=\"this.style.display='none'\"  \/>\n<h4>\n\t\tArribas Hortig\u00fcela, Lorena\n\t<\/h4>\n<h4>\n\t\t<a href=\"mailto:larribas@idibell.cat\" title=\"larribas@idibell.cat\" target=\"_blank\" rel=\"noopener\">\n\t\tlarribas@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n<h4>\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n<h4>\n\t\t<a href=\"https:\/\/twitter.com\/OlivaM_Onc\" title=\"@OlivaM_Onc\" target=\"_blank\" rel=\"noopener\">\n\t\t@OlivaM_Onc\n\t\t<\/a>\n\t<\/h4>\n<h2>\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-0\" data-index=\"0\" aria-selected=\"true\" aria-controls=\"fl-tabs--panel-0\" aria-expanded=\"true\" role=\"tab\" tabindex=\"0\">\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-1\" data-index=\"1\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-1\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-2\" data-index=\"2\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-2\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-3\" data-index=\"3\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-3\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t<a href=\"#\" id=\"fl-tabs--label-4\" data-index=\"4\" aria-selected=\"false\" aria-controls=\"fl-tabs--panel-4\" aria-expanded=\"false\" role=\"tab\" tabindex=\"0\">\t\t\t\tCol\u00b7laboradors\/es\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Ma\u00f1os Pujol, Manel<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es principals\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Oliva Bernal, Marc<\/li>\n<li>Arribas Hortig\u00fcela, Lorena<\/li>\n<\/ul>\n\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Handam Zavarce, Miriam<\/li>\n<li>Nogues Orp\u00ed, Julio<\/li>\n<li>Cisa Lluis, Enric<\/li>\n<li>Melero Luque, Mireia<\/li>\n<li>Bermejo Sergu, Oriol<\/li>\n<li>Tornero Salto, Jordi<\/li>\n<li>Goma Gallego, Montserrat<\/li>\n<li>Cruellas Taischik, Francesc<\/li>\n<li>Gonzalez Compta, Xavier<\/li>\n<li>Mari Roig, Antoni<\/li>\n<li>Lozano Borbalas, Alicia<\/li>\n<li>Plana Serrahima, Maria<\/li>\n<li>Cos Domingo, Monica<\/li>\n<li>Rodriguez Bel, Laura<\/li>\n<li>Arranz Obispo, Carlos<\/li>\n<li>Brenes Castro, Jesus<\/li>\n<li>Penella Prat, Anna<\/li>\n<li>Brunet Garcia, Aina<\/li>\n<li>Bartel Arensburg, Ricardo<\/li>\n<li>Mesalles Ruiz, Marta<\/li>\n<li>Portillo Medina, Alex<\/li>\n<li>Morla, Arnaud Gerard<\/li>\n<li>Cusc\u00f3 Albors, Silvia<\/li>\n<li>Fulla Camp\u00ed, Marta<\/li>\n<li>Lares Archer, Henri R<\/li>\n<\/ul>\n\t\t\t\t\t\tSuport cient\u00edfic\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Sospedra Martinez, Maria<\/li>\n<\/ul>\n\t\t\t\t\t\tCol\u00b7laboradors\/es\n\t\t\t\t\t\t\t\t\t\t\t<ul>\n<li>Rovira Casas, Aleix<\/li>\n<\/ul>\n<h2>\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/7323\" content=\"IDIBELL celebra el Kickoff Meeting AES 2019 sobre els Projectes de Recerca en Salut finan\u00e7ats per l&#8217;ISCIII\" \/><meta itemprop=\"datePublished\" content=\"2020-03-03\" \/><meta itemprop=\"dateModified\" content=\"2022-12-20\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/05\/foto_grup.jpg\" \/><meta itemprop=\"width\" content=\"1560\" \/><meta itemprop=\"height\" content=\"1017\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2020\/03\/idibell-celebra-el-kickoff-meeting-aes-2019-sobre-els-projectes-de-recerca-en-salut-financats-per-lisciii\/\" title=\"IDIBELL celebra el Kickoff Meeting AES 2019 sobre els Projectes de Recerca en Salut finan\u00e7ats per l&#8217;ISCIII\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2020\/03\/idibell-celebra-el-kickoff-meeting-aes-2019-sobre-els-projectes-de-recerca-en-salut-financats-per-lisciii\/\" title=\"IDIBELL celebra el Kickoff Meeting AES 2019 sobre els Projectes de Recerca en Salut finan\u00e7ats per l&#8217;ISCIII\">IDIBELL celebra el Kickoff Meeting AES 2019 sobre els Projectes de Recerca en Salut finan\u00e7ats per l&#8217;ISCIII<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t03\/03\/2020\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/7384\" content=\"La investigadora Purificaci\u00f3n Mu\u00f1oz rep el V premi Mart\u00ed Via\" \/><meta itemprop=\"datePublished\" content=\"2019-11-29\" \/><meta itemprop=\"dateModified\" content=\"2021-11-15\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2019\/11\/la-investigadora-purificacion-munoz-rep-el-v-premi-marti-via\/\" title=\"La investigadora Purificaci\u00f3n Mu\u00f1oz rep el V premi Mart\u00ed Via\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2019\/11\/la-investigadora-purificacion-munoz-rep-el-v-premi-marti-via\/\" title=\"La investigadora Purificaci\u00f3n Mu\u00f1oz rep el V premi Mart\u00ed Via\">La investigadora Purificaci\u00f3n Mu\u00f1oz rep el V premi Mart\u00ed Via<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t29\/11\/2019\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/7594\" content=\"El c\u00e0ncer de tu a tu: Pacients, metges, investigadors i activistes de la lluita contra el c\u00e0ncer dialoguen i s&#8217;obren a la ciutadania\" \/><meta itemprop=\"datePublished\" content=\"2018-09-13\" \/><meta itemprop=\"dateModified\" content=\"2021-07-28\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2020\/05\/elcancerdetuatu2.jpg\" \/><meta itemprop=\"width\" content=\"700\" \/><meta itemprop=\"height\" content=\"409\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2018\/09\/el-cancer-de-tu-a-tu-pacients-metges-investigadors-i-activistes-de-la-lluita-contra-el-cancer-dialoguen-i-sobren-a-la-ciutadania\/\" title=\"El c\u00e0ncer de tu a tu: Pacients, metges, investigadors i activistes de la lluita contra el c\u00e0ncer dialoguen i s&#8217;obren a la ciutadania\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2018\/09\/el-cancer-de-tu-a-tu-pacients-metges-investigadors-i-activistes-de-la-lluita-contra-el-cancer-dialoguen-i-sobren-a-la-ciutadania\/\" title=\"El c\u00e0ncer de tu a tu: Pacients, metges, investigadors i activistes de la lluita contra el c\u00e0ncer dialoguen i s&#8217;obren a la ciutadania\">El c\u00e0ncer de tu a tu: Pacients, metges, investigadors i activistes de la lluita contra el c\u00e0ncer dialoguen i s&#8217;obren a la ciutadania<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t13\/09\/2018\t\t\t\t\t\t\t\n\t<meta itemscope itemprop=\"mainEntityOfPage\" itemtype=\"https:\/\/schema.org\/WebPage\" itemid=\"http:\/\/9543\" content=\"La p\u00e8rdua d&#8217;una prote\u00efna fa 'saltar' el tumor al gangli limf\u00e0tic\" \/><meta itemprop=\"datePublished\" content=\"2012-03-06\" \/><meta itemprop=\"dateModified\" content=\"2023-03-02\" \/><meta itemprop=\"name\" content=\"IDIBELL\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2023\/03\/cropped-Marca-B.png\"\/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/author\/erigin\/\" \/><meta itemprop=\"name\" content=\"Idibell\" \/><meta itemprop=\"url\" content=\"https:\/\/idibell.cat\/wp-content\/uploads\/2012\/03\/Clipboard-2-1.jpg\" \/><meta itemprop=\"width\" content=\"1366\" \/><meta itemprop=\"height\" content=\"768\" \/><meta itemprop=\"interactionType\" content=\"https:\/\/schema.org\/CommentAction\" \/><meta itemprop=\"userInteractionCount\" content=\"0\" \/>\t\n\t\t\t\t<a href=\"https:\/\/idibell.cat\/2012\/03\/la-perdua-duna-proteina-fa-saltar-el-tumor-al-gangli-limfatic\/\" title=\"La p\u00e8rdua d&#8217;una prote\u00efna fa 'saltar' el tumor al gangli limf\u00e0tic\"><\/a>\n\t\t\t<a href=\"https:\/\/idibell.cat\/2012\/03\/la-perdua-duna-proteina-fa-saltar-el-tumor-al-gangli-limfatic\/\" title=\"La p\u00e8rdua d&#8217;una prote\u00efna fa 'saltar' el tumor al gangli limf\u00e0tic\">La p\u00e8rdua d&#8217;una prote\u00efna fa &#8216;saltar&#8217; el tumor al gangli limf\u00e0tic<\/a>\n\t\t\tBy <a href=\"https:\/\/idibell.cat\/author\/erigin\/\">Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t  |  \n\t\t\t\t\t\t\t\t\t06\/03\/2012\t\t\t\t\t\t\t\n\t\t<!-- .pp-content-posts -->\n\n","protected":false},"excerpt":{"rendered":"<p>Malalties de cap i coll Resum El grup de recerca de cap i coll, en la seva l\u00ednia de recerca oncol\u00f2gica, estudia noves dianes terap\u00e8utiques i biomarcadors predictius de resposta a QMT, RT i immunoter\u00e0pia, el paper del virus del papil\u00b7loma hum\u00e0 (HPV) i el maneig diferencial dels tumors HPV+, el tractament trans-oral del C\u00e0ncer [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":448,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-1906","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 18:27:13","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=1906"}],"version-history":[{"count":10,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1906\/revisions"}],"predecessor-version":[{"id":26001,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/1906\/revisions\/26001"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/448"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=1906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}